Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
April 13, 2022 16:11 ET
|
Supernus Pharmaceuticals, Inc.
Annual Report on Form 10-K filed on April 13, 2022Reiterates full year 2022 financial guidance provided on February 28, 2022 and reiterated on April 4, 2022 ROCKVILLE, Md., April 13, 2022 (GLOBE...
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance
April 04, 2022 17:00 ET
|
Supernus Pharmaceuticals, Inc.
Annual Report on Form 10-K for fiscal year ended December 31, 2021 to be filed in the near termReiterates full year 2022 financial guidance provided on February 28, 2022 ROCKVILLE, Md., April 04,...
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance
March 17, 2022 08:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in Annual Cowen Health Care Conference
March 02, 2022 08:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022 16:05 ET
|
Supernus Pharmaceuticals, Inc.
Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020SPN-830 (apomorphine infusion device) NDA accepted for review by FDA; PDUFA date early...
Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
February 22, 2022 16:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA
February 22, 2022 08:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
December 08, 2021 08:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Pharmaceuticals Targeted in Ransomware Incident
November 24, 2021 18:58 ET
|
Supernus Pharmaceuticals, Inc.
The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations No ransom payments have been made by the Company ROCKVILLE, Md., Nov. 24,...
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
November 24, 2021 09:12 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas...